MedPath

Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
Psychoses
Interventions
Registration Number
NCT00159133
Lead Sponsor
Heinrich-Heine University, Duesseldorf
Brief Summary

Prodrome based early intervention with an antipsychotic drug vs. benzodiazepine was applied in patients with first episode schizophrenia after one year neuroleptic maintenance treatment. Two groups of patients were followed over a period of 1 year: one further on under maintenance neuroleptic treatment, the other one after stepwise drug discontinuation.

Detailed Description

In case of early signs of a relapse prodrome based early intervention with an antipsychotic drug (Haloperidol, Risperidone and other) vs. benzodiazepine (Lorazepam) was applied in patients with first episode schizophrenia after one year neuroleptic maintenance treatment. Two groups of patients were followed over a period of 1 year: one further on under maintenance neuroleptic treatment (Haloperidol, Risperidone and other) , the other one after stepwise drug discontinuation.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
71
Inclusion Criteria
  • First-episode in schizophrenia (according ICD-10 F20)
  • Age between 18 and 55
  • Informed consent
  • One year neuroleptic maintenance treatment
Exclusion Criteria
  • Residence outside of the catchment area
  • Legal reasons
  • Insufficient knowledge of the german language
  • Substance abuse or addiction
  • Pregnancy
  • Serious physical illness
  • Organic brain disease
  • Contraindication to neuroleptic treatment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1antipsychotics vs. Lorazepam (Drugs)Early intervention with benzodiazepines in case of prodromal symptoms of an impending relapse
2antipsychotics vs. Lorazepam (Drugs)Early intervention with antipsychotics in case of prodromal symptoms of an impending relapse
Primary Outcome Measures
NameTimeMethod
relapse rate1 year
Secondary Outcome Measures
NameTimeMethod
quality of life1 year
social and cognitive functioning1 year
psychopathology1 year
side-effects1 year
drop-out1 year

Trial Locations

Locations (1)

German Research Network on Schizophrenia, Department of Psychiatry and Psychotherapy at the Heinrich-Heine-University Düsseldorf

🇩🇪

Düsseldorf, North Rhine-Westphalia, Germany

© Copyright 2025. All Rights Reserved by MedPath